Table 3.
Distribution of the antiretroviral resistance mutations and major envelope tropism found across the 23 HIV-1 genome sequences analyzed.
| Patient | Protease Mutations (Coverage; Frequency) | Reverse Transcriptase Mutations (Coverage; Frequency) | RT Connection Mutations (Coverage; Frequency) | RT RNase H Mutation | Integrase Mutations (Coverage; Frequency) | Envelope Mutations (Coverage; Frequency) | HAART Regimen | Tropism 1 | Subtype/URF |
|---|---|---|---|---|---|---|---|---|---|
| 1 | - | M184V (11,979; 2.0%) | - | - | S147G (8945; 1.1%) | - | AZT + 3TC + NVP | 100.0% X4/R5X4 | B |
| 2 # | - | - | - | - | R263K (2201; 6.2%) | - | AZT + 3TC + EFV | 63.0% X4/R5X4 | B |
| 3 | - | - | - | - | - | - | TDF + 3TC + EFV | 97.2% R5 | B |
| 5 | I47V (3589; 10.3%) | - | - | - | - | - | AZT + 3TC + ATV | 100% R5 | B |
| 8 | - | NA | E399D (2701; 99.2%) | - | - | - | TDF + 3TC + EFV | 97.1% R5 | BC |
| 11 | D30N (8012; 2.8%) M46I (8639; 1.9%) |
M41L (5444; 99.8%) | T369V (9726; 39.6%) E399G (8334; 4.9%) |
- | - | - | TDF + 3TC + EFV | 96.1% R5 | BF |
| 12 | - | - | - | - | - | - | TDF + 3TC + EFV | 84.8% R5 | B |
| 13 | - | E138K (4909; 1.3%) | - | - | - | V38A (2151; 3.0%) | TDF + 3TC + EFV | 99.0% X4/R5X4 | B |
| 14 | - | - | - | NA | R263K * (1776; 11.0%) | - | AZT + 3TC + LPV/r | 97.8% R5 | B |
| 15 | - | - | E399G (14,872; 1.5%) | - | - | - | TDF + 3TC + EFV | 97.7% R5 | B |
| 16 | D30N (4574; 49.3%) M46I (4378; 45.6%) |
- | - | - | - | - | AZT + 3TC + FPV/r | NA | B |
| 18 | - | A62V (4116; 1.0%) | - | - | - | NA | TDF + 3TC + EFV | 91.6% R5 | B |
| 19 | - | NA | A376S (6663; 99.9%) | - | - | - | AZT + 3TC + EFV | 99.6% R5 | B |
| 20 | - | - | - | NA | NA | NA | TDF + 3TC + EFV | 100.0% R5 | B |
| 21 | - | L210W (12,583; 100.0%) | - | - | - | - | TDF + EFV + FTC | 99.3% R5 | B |
| 22 | - | NA | A376S * (1082; 94.9%) | - | - | - | TDF + 3TC + EFV | 100.0% R5 | B |
| 23 | - | - | - | - | T97A (4113; 2.1%) | - | TDF + 3TC + EFV | 96.0% R5 | B |
| 26 | - | NA | NA | NA | NA | - | TDF + 3TC + EFV | 100.0% X4/R5X4 | B |
| 27 | - | NA | - | - | - | - | TDF + 3TC + EFV | 99.9% R5 | B |
| 28 | - | M41L (5791; 99.5%) D67N (6465; 72.9%) K70R (6475; 77.2%) T215Y (9219; 38.7%) |
E399D (2051; 99.9%) | NA | NA | - | TDF + 3TC + EFV | 99.1% R5 | BF |
| 29 | - | - | E399D (5209; 100.0%) | - | T66I (7444; 31.0%) | NA | TDF + 3TC + EFV | 99.7% X4/R5X4 | B |
| 31 | - | M184V (2708; 1.3%) | - | - | - | - | TDF + 3TC + EFV | 100.0% R5 | B |
| 32 | - | V179D (7146; 99.3%) M184V (7127; 8.0%) |
- | - | - | - | TDF + 3TC + EFV | 100.0% R5 | BF |
# The near full-length genomes are in bold; NA, not available; -, no mutations found; *, only partial sequence available; 1 X4/R5X4: CXC chemokine receptor 4 (CXCR4) and/or CXCR4/CC chemokine receptor 5 (CCR5) tropism profile; R5: CCR5 tropism profile.